These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 36357291)

  • 1. Guillain-Barré syndrome temporally associated with COVID-19 vaccines in Victoria, Australia.
    Osowicki J; Morgan HJ; Harris A; Clothier HJ; Buttery JP; Kiers L; Crawford NW;
    Vaccine; 2022 Dec; 40(52):7579-7585. PubMed ID: 36357291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the adverse events of Oxford-AstraZeneca, Pfizer-BioNTech, Moderna, and Johnson and Johnson COVID-19 vaccination on Guillain-Barré Syndrome.
    Meo SA; Shaikh N; Abukhalaf FA; Meo AS
    Sci Rep; 2024 Aug; 14(1):18767. PubMed ID: 39138276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 vaccination and Guillain-Barré syndrome: analyses using the National Immunoglobulin Database.
    Keh RYS; Scanlon S; Datta-Nemdharry P; Donegan K; Cavanagh S; Foster M; Skelland D; Palmer J; Machado PM; Keddie S; Carr AS; Lunn MP;
    Brain; 2023 Feb; 146(2):739-748. PubMed ID: 35180300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States.
    Abara WE; Gee J; Marquez P; Woo J; Myers TR; DeSantis A; Baumblatt JAG; Woo EJ; Thompson D; Nair N; Su JR; Shimabukuro TT; Shay DK
    JAMA Netw Open; 2023 Feb; 6(2):e2253845. PubMed ID: 36723942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization: Analysis of a nationwide registry of recipients of 81 million doses of seven vaccines.
    García-Grimshaw M; Galnares-Olalde JA; Bello-Chavolla OY; Michel-Chávez A; Cadena-Fernández A; Briseño-Godínez ME; Antonio-Villa NE; Núñez I; Gutiérrez-Romero A; Hernández-Vanegas L; Del Mar Saniger-Alba M; Carrillo-Mezo R; Ceballos-Liceaga SE; Carbajal-Sandoval G; Flores-Silva FD; Díaz-Ortega JL; Cortes-Alcalá R; Pérez-Padilla JR; López-Gatell H; Chiquete E; Reyes-Terán G; Arauz A; Valdés-Ferrer SI
    Eur J Neurol; 2022 Nov; 29(11):3368-3379. PubMed ID: 35841212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink.
    Hanson KE; Goddard K; Lewis N; Fireman B; Myers TR; Bakshi N; Weintraub E; Donahue JG; Nelson JC; Xu S; Glanz JM; Williams JTB; Alpern JD; Klein NP
    JAMA Netw Open; 2022 Apr; 5(4):e228879. PubMed ID: 35471572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rare cases of Guillain-Barré syndrome after COVID-19 vaccination, Germany, December 2020 to August 2021.
    Lehmann HC; Oberle D; Keller-Stanislawski B; Rieck T; Streit R
    Euro Surveill; 2023 Jun; 28(24):. PubMed ID: 37318764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations of Guillain-Barré syndrome with coronavirus disease 2019 vaccination: Disproportionality analysis using the World Health Organization pharmacovigilance database.
    Kim JE; Park J; Min YG; Hong YH; Song TJ
    J Peripher Nerv Syst; 2022 Sep; 27(3):206-214. PubMed ID: 35751472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune thrombocytopenia following immunisation with Vaxzevria ChadOx1-S (AstraZeneca) vaccine, Victoria, Australia.
    Gordon SF; Clothier HJ; Morgan H; Buttery JP; Phuong LK; Monagle P; Chunilal S; Wood EM; Tran H; Szer J; Crawford NW;
    Vaccine; 2021 Nov; 39(48):7052-7057. PubMed ID: 34756770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-marketing active surveillance of Guillain Barré Syndrome following COVID-19 vaccination in persons aged ≥12 years in Italy: A multi-database self-controlled case series study.
    Morciano C; Spila Alegiani S; Menniti Ippolito F; Belleudi V; Trifirò G; Zanoni G; Puccini A; Sapigni E; Mores N; Leoni O; Monaco G; Clagnan E; Zappetti C; Bovo E; Cutillo M; Da Cas R; Massari M
    PLoS One; 2024; 19(1):e0290879. PubMed ID: 38241309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guillain-Barré syndrome after COVID-19 vaccines: A Tunisian case series.
    Berrim K; Lakhoua G; Zaiem A; Charfi O; Aouinti I; Kastalli S; Daghfous R; El Aidli S
    Br J Clin Pharmacol; 2023 Feb; 89(2):574-578. PubMed ID: 36398559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guillain-Barré syndrome after COVID-19 vaccination: A systematic review and analysis of case reports.
    Abuawwad MT; Taha MJJ; Taha AJ; Kozaa YA; Falah O; Abuawwad IT; Hammad EM; Mahmoud AA; Aladawi M; Serhan HA
    Clin Neurol Neurosurg; 2024 Mar; 238():108183. PubMed ID: 38401232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of COVID-19 vaccine type on Guillain-Barré syndrome: Two cases and a literature review.
    Lee HY; Lien WC
    Hum Vaccin Immunother; 2023 Dec; 19(1):2171231. PubMed ID: 36919452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals.
    Faksova K; Walsh D; Jiang Y; Griffin J; Phillips A; Gentile A; Kwong JC; Macartney K; Naus M; Grange Z; Escolano S; Sepulveda G; Shetty A; Pillsbury A; Sullivan C; Naveed Z; Janjua NZ; Giglio N; Perälä J; Nasreen S; Gidding H; Hovi P; Vo T; Cui F; Deng L; Cullen L; Artama M; Lu H; Clothier HJ; Batty K; Paynter J; Petousis-Harris H; Buttery J; Black S; Hviid A
    Vaccine; 2024 Apr; 42(9):2200-2211. PubMed ID: 38350768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of Guillain-Barré Syndrome Following COVID-19 Vaccines: A Nationwide Self-Controlled Case Series Study.
    Le Vu S; Bertrand M; Botton J; Jabagi MJ; Drouin J; Semenzato L; Weill A; Dray-Spira R; Zureik M
    Neurology; 2023 Nov; 101(21):e2094-e2102. PubMed ID: 37788935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of COVID-19 vaccination and acute neurological events: A self-controlled case series in England using the OpenSAFELY platform.
    Walker JL; Schultze A; Tazare J; Tamborska A; Singh B; Donegan K; Stowe J; Morton CE; Hulme WJ; Curtis HJ; Williamson EJ; Mehrkar A; Eggo RM; Rentsch CT; Mathur R; Bacon S; Walker AJ; Davy S; Evans D; Inglesby P; Hickman G; MacKenna B; Tomlinson L; Ca Green A; Fisher L; Cockburn J; Parry J; Hester F; Harper S; Bates C; Evans SJ; Solomon T; Andrews NJ; Douglas IJ; Goldacre B; Smeeth L; McDonald HI
    Vaccine; 2022 Jul; 40(32):4479-4487. PubMed ID: 35715350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guillain-Barré syndrome and COVID-19 vaccination: a systematic review and meta-analysis.
    Censi S; Bisaccia G; Gallina S; Tomassini V; Uncini A
    J Neurol; 2024 Mar; 271(3):1063-1071. PubMed ID: 38233678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The short term safety of COVID-19 vaccines in Australia: AusVaxSafety active surveillance, February - August 2021.
    Deng L; Glover C; Dymock M; Pillsbury A; Marsh JA; Quinn HE; Leeb A; Cashman P; Snelling TL; Wood N; Macartney K
    Med J Aust; 2022 Aug; 217(4):195-202. PubMed ID: 35781813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global burden of vaccine-associated Guillain-Barré syndrome over 170 countries from 1967 to 2023.
    Jeong YD; Park S; Lee S; Jang W; Park J; Lee K; Lee J; Kang J; Udeh R; Rahmati M; Yeo SG; Smith L; Lee H; Yon DK
    Sci Rep; 2024 Oct; 14(1):24561. PubMed ID: 39427003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world data on the incidence and risk of Guillain-Barré syndrome following SARS-CoV-2 vaccination: a prospective surveillance study.
    Ha J; Park S; Kang H; Kyung T; Kim N; Kim DK; Kim H; Bae K; Song MC; Lee KJ; Lee E; Hwang BS; Youn J; Seok JM; Park K
    Sci Rep; 2023 Mar; 13(1):3773. PubMed ID: 36882454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.